Blueprint Medicines Corporation (NASDAQ:BPMC) reported Q2 2017 earnings this Morning, coming in at ($0.86) per share, missing Wall Street’s estimates of ($0.75) per Share. Revenue for the quarter came in at $5.89 million missing the streets estimates of $5.96 million
Analyst Coverage For Blueprint Medicines Corporation (NASDAQ:BPMC)
These are 7 Buy Ratings .
The current consensus rating for Blueprint Medicines Corporation (NASDAQ:BPMC) is Buy (Score: 3.00) with a consensus target price of $47.88 , a potential (10.03% downside)Recent Insider Trading for Blueprint Medicines Corporation (NASDAQ:BPMC)
- On 7/5/2017 Daniel Lynch, Director, sold 7,500 with an average share price of $55.06 per share and the total transaction amounting to $412,950.00.
- On 7/5/2017 Kate Haviland, Insider, sold 7,265 with an average share price of $54.66 per share and the total transaction amounting to $397,104.90.
- On 6/28/2017 Daniel Lynch, Director, sold 32,500 with an average share price of $50.28 per share and the total transaction amounting to $1,634,100.00.
- On 6/28/2017 Jeffrey W Albers, CEO, sold 20,000 with an average share price of $50.47 per share and the total transaction amounting to $1,009,400.00.
- On 6/28/2017 Kate Haviland, Insider, sold 6,357 with an average share price of $50.00 per share and the total transaction amounting to $317,850.00.
- On 3/16/2017 Mark J Levin, Major Shareholder, sold 30,000 with an average share price of $40.88 per share and the total transaction amounting to $1,226,400.00.
Recent Trading for Blueprint Medicines Corporation (NASDAQ:BPMC) Shares of Blueprint Medicines Corporation closed the previous trading session at 51.15 down -2.07 -3.89% with 283,225 shares trading hands.